Stem Cell Reports (Oct 2016)

Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation

  • Sun Young Chung,
  • Sarah Kishinevsky,
  • Joseph R. Mazzulli,
  • John Graziotto,
  • Ana Mrejeru,
  • Eugene V. Mosharov,
  • Lesly Puspita,
  • Parvin Valiulahi,
  • David Sulzer,
  • Teresa A. Milner,
  • Tony Taldone,
  • Dimitri Krainc,
  • Lorenz Studer,
  • Jae-won Shim

DOI
https://doi.org/10.1016/j.stemcr.2016.08.012
Journal volume & issue
Vol. 7, no. 4
pp. 664 – 677

Abstract

Read online

Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related proteins Parkin and PINK1, suggesting that pathways implicated in these monogenic forms could play a more general role in PD. We demonstrate that the identification of disease-related phenotypes in PD-patient-specific induced pluripotent stem cell (iPSC)-derived midbrain dopamine (mDA) neurons depends on the type of differentiation protocol utilized. In a floor-plate-based but not a neural-rosette-based directed differentiation strategy, iPSC-derived mDA neurons recapitulate PD phenotypes, including pathogenic protein accumulation, cell-type-specific vulnerability, mitochondrial dysfunction, and abnormal neurotransmitter homeostasis. We propose that these form a pathogenic loop that contributes to disease. Our study illustrates the promise of iPSC technology for examining PD pathogenesis and identifying therapeutic targets.